Loading stock data…
Kailera Therapeutics, Inc. (KLRA)
$21.67+0.84 (+4.03%)
Market ClosedLast close Jun 29
Kailera Therapeutics, Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $0 | $0 |
| Gross Profit | — | — |
| Operating Income | -$84.66M↓ | -$20.46M |
| Net Income | -$78.86M↓ | -$17.98M |
Peer Comparison
JNJUNHPFE
Fundamentals
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectabl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.54B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
22.41%
Volume
Today's trading volume
575,199
Recent News
Kardigan rises in Nasdaq debut after upsized $400 million IPO
June 18 () - Kardigan's shares rose 1.6% in their Nasdaq debut on Thursday, after the heart drug developer raised $400 million in an upsized U.
3 Under-the-Radar Stocks to Buy and Hold for a Decade
All three could become highly prominent biotech companies within 10 years.
‘I worry deeply about bioterrorism’: Is Europe sufficiently prepared for another pandemic?
Internationally renowned for their life-saving Covid vaccine, what is Moderna doing now? Their CEO joins us in the studio to discuss bioterrorism, pandemic preparedness and cancer treatment.View on euronews
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?
It's important to consider your comfort with risk before diving in.
How to Play PBLS Stock After the Parabilis IPO
Parabilis stock soared on its Nasdaq debut, but a deeper dive suggests PBLS shares could extend gains further through the remainder of 2026.